Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, insulin-infusion device specialist Insulet
With that in mind, let's take a closer look at Insulet's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Bedford, Mass. (2000)|
|Market Cap||$912.6 million|
|Trailing-12-Month Revenue||$152.3 million|
|Management||CEO Duane DeSisto (since 2003)
CFO Brian Roberts (since 2009)
|Return on Equity (average, past 3 years)||(113.1%)|
|Cash/Debt||$94.0 million / $108.5 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 37% of the 107 members who have rated Insulet believe the stock will underperform the S&P 500 going forward.
The future in this space belongs to the company that can make and market "The Artificial Pancreas", the device that simultaneously measures changes in glucose and reponds with an immediate and correct insulin dosage. [Insulet's] problem is that it's up against heavy-weights and [outgunned] by their marketeers. I cannot see it getting bought out. It will, I fear, slip and stagnate.
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.